HealthQuill lecanemab
Alzheimer's disease has an initial silent and slow phase before the second stage of a destructive accumulation of plaques, tangles and other symptoms occurs, a brain-mapping study funded by the National Institutes of Health finds.
Health Uncategorized

EU regulators reverse course, approve Alzheimer’s drug Leqembi

HQ Team November 19, 2024: The European Medicines Agency (EMA) granted conditional approval for lecanemab, for the treatment of early Alzheimer’s disease in.

Read More
Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority for leqembi, an investigational drug to treat early onset of Alzheimer’s disease.
Drugs Health Medical Pharma

Japan’s Eisai seeks marketing nod for Alzheimer’s drug in South Korea

HQ Team June 8, 2023: Japan’s Eisai Co and Biogen Inc., have submitted a marketing authorisation application with the South Korean health authority.

Read More